pegsitacianine for Peritoneal Carcinomatosis

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Peritoneal Carcinomatosispegsitacianine - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing a new cancer-detecting agent that may help improve outcomes for patients with peritoneal carcinomatosis.

Eligible Conditions
  • Peritoneal Carcinomatosis

Treatment Effectiveness

Study Objectives

1 Primary · 2 Secondary · Reporting Duration: 30 days

1 day
Clinically Significant Events (CSE)
30 days
Pegsitacianine safety
7 days
Pegsitacianine fluorescence and imaging performance

Trial Safety

Trial Design

1 Treatment Group

Fluorescence imaging with pegsitacianine
1 of 1

Experimental Treatment

60 Total Participants · 1 Treatment Group

Primary Treatment: pegsitacianine · No Placebo Group · Phase 2

Fluorescence imaging with pegsitacianine
Drug
Experimental Group · 1 Intervention: pegsitacianine · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 30 days

Who is running the clinical trial?

OncoNano Medicine, Inc.Lead Sponsor
2 Previous Clinical Trials
70 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 1 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you: